147 related articles for article (PubMed ID: 31206617)
1. An Analysis of Follow-On Development in New Drug Classes, January 1986-June 2018.
Lanthier ML; Kerr KW; Miller KL
Clin Pharmacol Ther; 2019 Nov; 106(5):1125-1132. PubMed ID: 31206617
[TBL] [Abstract][Full Text] [Related]
2. Characteristics of Recent Generic Drug Approvals by the US Food and Drug Administration.
Jiao K; Gupta R; Fox E; Kesselheim A; Ross JS
JAMA Netw Open; 2019 Oct; 2(10):e1913029. PubMed ID: 31603482
[TBL] [Abstract][Full Text] [Related]
3. Muddied messages about FDA.
Miller HI
Nat Biotechnol; 2003 Jul; 21(7):732-3. PubMed ID: 12833084
[No Abstract] [Full Text] [Related]
4. The impact of incremental innovation in biopharmaceuticals: drug utilisation in original and supplemental indications.
Berndt ER; Cockburn IM; Grépin KA
Pharmacoeconomics; 2006 Dec; 24 Suppl 2():69-86. PubMed ID: 23389490
[TBL] [Abstract][Full Text] [Related]
5. The economics of follow-on drug research and development: trends in entry rates and the timing of development.
DiMasi JA; Paquette C
Pharmacoeconomics; 2004; 22(2 Suppl 2):1-14. PubMed ID: 15660473
[TBL] [Abstract][Full Text] [Related]
6. 2020 in review: FDA approvals of new medicines.
Kinch MS; Kraft Z; Schwartz T
Drug Discov Today; 2021 Dec; 26(12):2794-2799. PubMed ID: 34252611
[TBL] [Abstract][Full Text] [Related]
7. The Pharmaceutical Industry in 2017. An Analysis of FDA Drug Approvals from the Perspective of Molecules.
de la Torre BG; Albericio F
Molecules; 2018 Feb; 23(3):. PubMed ID: 29495494
[TBL] [Abstract][Full Text] [Related]
8. Security market reaction to FDA fast track designations.
Anderson CW; Zhang Y
J Health Care Finance; 2010; 37(2):27-48. PubMed ID: 21294437
[TBL] [Abstract][Full Text] [Related]
9. 2018 in review: FDA approvals of new molecular entities.
Kinch MS; Griesenauer RH
Drug Discov Today; 2019 Sep; 24(9):1710-1714. PubMed ID: 31158510
[TBL] [Abstract][Full Text] [Related]
10. The impact of external innovation on new drug approvals: A retrospective analysis.
Liu X; Thomas CE; Felder CC
Int J Pharm; 2019 May; 563():273-281. PubMed ID: 30664998
[TBL] [Abstract][Full Text] [Related]
11. A forensic analysis of drug targets from 2000 through 2012.
Munos B
Clin Pharmacol Ther; 2013 Sep; 94(3):407-11. PubMed ID: 23756372
[TBL] [Abstract][Full Text] [Related]
12. Affordability and availability of off-patent drugs in the United States-the case for importing from abroad: observational study.
Gupta R; Bollyky TJ; Cohen M; Ross JS; Kesselheim AS
BMJ; 2018 Mar; 360():k831. PubMed ID: 29555641
[TBL] [Abstract][Full Text] [Related]
13. Updated trends in US brand-name and generic drug competition.
Grabowski H; Long G; Mortimer R; Boyo A
J Med Econ; 2016 Sep; 19(9):836-44. PubMed ID: 27064194
[TBL] [Abstract][Full Text] [Related]
14. Decline in the Development of New Anesthetics.
Vlassakov KV; Kissin I
Trends Pharmacol Sci; 2016 May; 37(5):344-352. PubMed ID: 26922254
[TBL] [Abstract][Full Text] [Related]
15. 2016 in review: FDA approvals of new molecular entities.
Griesenauer RH; Kinch MS
Drug Discov Today; 2017 Nov; 22(11):1593-1597. PubMed ID: 28687460
[TBL] [Abstract][Full Text] [Related]
16. Incentives for orphan drug research and development in the United States.
Seoane-Vazquez E; Rodriguez-Monguio R; Szeinbach SL; Visaria J
Orphanet J Rare Dis; 2008 Dec; 3():33. PubMed ID: 19087348
[TBL] [Abstract][Full Text] [Related]
17. Biosimilar competition in the United States: statutory incentives, payers, and pharmacy benefit managers.
Falit BP; Singh SC; Brennan TA
Health Aff (Millwood); 2015 Feb; 34(2):294-301. PubMed ID: 25646110
[TBL] [Abstract][Full Text] [Related]
18. Innovating by developing new uses of already-approved drugs: trends in the marketing approval of supplemental indications.
DiMasi JA
Clin Ther; 2013 Jun; 35(6):808-18. PubMed ID: 23726388
[TBL] [Abstract][Full Text] [Related]
19. The Pharmaceutical Industry in 2019. An Analysis of FDA Drug Approvals from the Perspective of Molecules.
de la Torre BG; Albericio F
Molecules; 2020 Feb; 25(3):. PubMed ID: 32050446
[TBL] [Abstract][Full Text] [Related]
20. New drug approvals for 2002.
Frantz S; Smith A
Nat Rev Drug Discov; 2003 Feb; 2(2):95-6. PubMed ID: 12572538
[No Abstract] [Full Text] [Related]
[Next] [New Search]